高级检索
当前位置: 首页 > 详情页

Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, China [2]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006, China [3]Post-doctoral Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China [4]College of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. [5]School of Chinese Medicine, Hong Kong Baptist University, 999077 Kowloon Tong, Hong Kong [6]Department of Mammary Disease, Panyu Hospital of Chinese Medicine, Guangzhou 511400, China
出处:
ISSN:

摘要:
Breast cancer stem cells (BCSCs) are considered to be the root of breast cancer occurrence and progression. However, the characteristics and regulatory mechanisms of BCSCs metabolism have been poorly revealed, which hinders the development of metabolism-targeted treatment strategies for BCSCs elimination. Herein, we demonstrated that the downregulation of Caveolin-1 (Cav-1) usually occurred in BCSCs and was associated with a metabolic switch from mitochondrial respiration to aerobic glycolysis. Meanwhile, Cav-1 could inhibit the self-renewal capacity and aerobic glycolysis activity of BCSCs. Furthermore, Cav-1 loss was associated with accelerated mammary-ductal hyperplasia and mammary-tumor formation in transgenic mice, which was accompanied by enrichment and enhanced aerobic glycolysis activity of BCSCs. Mechanistically, Cav-1 could promote Von Hippel-Lindau (VHL)-mediated ubiquitination and degradation of c-Myc in BCSCs through the proteasome pathway. Notably, epithelial Cav-1 expression significantly correlated with a better overall survival and delayed onset age of breast cancer patients. Together, our work uncovers the characteristics and regulatory mechanisms of BCSCs metabolism and highlights Cav-1-targeted treatments as a promising strategy for BCSCs elimination.

基金:

基金编号: 81703749, 81703764, 81973526, and 81873306

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 生物
小类 | 2 区 细胞生物学
最新[2025]版:
大类 | 1 区 生物学
小类 | 2 区 细胞生物学
JCR分区:
出版当年[2018]版:
Q1 CELL BIOLOGY
最新[2023]版:
Q1 CELL BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, China [2]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006, China [3]Post-doctoral Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
共同第一作者:
通讯作者:
通讯机构: [1]Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510006, China [2]Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510006, China [3]Post-doctoral Research Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, China [4]College of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China. [5]School of Chinese Medicine, Hong Kong Baptist University, 999077 Kowloon Tong, Hong Kong [6]Department of Mammary Disease, Panyu Hospital of Chinese Medicine, Guangzhou 511400, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号